Evidence map›Paper›PMID 36711909›Full record

ArticlebioRxiv : the preprint server for biology2023

Novel keto-alkyl-pyridinium antifungal molecules active in models of in vivo

Sarah R Beattie, Taiwo Esan, Robert Zarnowski, Emily Eix, Jeniel E Nett, David R Andes, Timothy Hagen, Damian J Krysan

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sarah R BeattieDepartment of Pediatrics, Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City IA.
Taiwo EsanDepartment of Chemistry and Biochemistry, Northern Illinois University, 1425 West Lincoln Highway, DeKalb IL.
Robert ZarnowskiDepartment of Medicine, Section of Infectious Disease, University of Wisconsin, Madison WI.
Emily EixDepartment of Medicine, Section of Infectious Disease, University of Wisconsin, Madison WI.
Jeniel E NettDepartment of Medicine, Section of Infectious Disease, University of Wisconsin, Madison WI.
David R AndesDepartment of Medicine, Section of Infectious Disease, University of Wisconsin, Madison WI.
Timothy HagenDepartment of Chemistry and Biochemistry, Northern Illinois University, 1425 West Lincoln Highway, DeKalb IL.
Damian J KrysanDepartment of Pediatrics, Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City IA.
University of Wisconsin–Madison · USNorthern Illinois University · USUniversity of Iowa · US

Funding

Vesicle-mediated drug resistance of Candida albicans biofilmR01AI073289 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R, MITCHELL, AARON P · 2008 to 2025
$7.9M
Discovery and optimization of antifungal acetyl CoA synthetase inhibitorsR01AI161973 · NIAID · UNIVERSITY OF IOWA · PI KRYSAN, DAMIAN J · 2021 to 2025
$3.0M
Hit-to-lead optimization of broad spectrum antifungal phenothiazinesR21AI164578 · NIAID · UNIVERSITY OF IOWA · PI KRYSAN, DAMIAN J, MEYERS, MARVIN J · 2021 to 2022
$434k
Development of a high throughput-compatible assay for screening filamentous fungiF32AI145160 · NIAID · UNIVERSITY OF IOWA · PI BEATTIE, SARAH R. · 2020 to 2022
$185k
NIAID NIH HHS F32 AI145160NIAID NIH HHS R01 AI073289NIAID NIH HHS R01 AI161973NIAID NIH HHS R21 AI164578
6 · The paper itself

Abstract

New antifungal therapies are needed for both systemic, invasive infections as well as superficial infections of mucosal and skin surfaces as well as biofilms associated with medical devices. The resistance of biofilm and biofilm-like growth phases of fungi contributes to the poor efficacy of systemic therapies to non-systemic infections. Here, we describe the identification and characterization of a novel keto-alkyl-pyridinium scaffold with broad spectrum activity (2-16 µg/mL) against medically important yeasts and moulds, including clinical isolates resistant to azoles and/or echinocandins. Furthermore, these keto-alkyl-pyridinium agents retain substantial activity against biofilm phase yeast and have direct activity against hyphal

Identifiers

PMID36711909
PMCPMC9882332
OpenAlexW4317583942

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.